A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)
Latest Information Update: 21 Mar 2022
At a glance
- Drugs Avasopasem manganese (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Hypoxic respiratory failure
- Focus Therapeutic Use
- Sponsors Galera Therapeutics
- 09 Jul 2021 Status changed from recruiting to discontinued.
- 10 Nov 2020 According to a Galera Therapeutics media release, data from this trial is expected in the first half of 2021.
- 18 Sep 2020 New trial record